Ocular Therapeutix, Inc.
AXPAXLI
wet AMD
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on AXPAXLI for wet AMD is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“AXPAXLI New Drug Application (NDA) submission for wet AMD remains on track based on the SOL-1 Week 52 trial results, subject to ongoing formal discussions with the U.S. FDA.”